pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Haisco Pharmaceutical partners with ARCH Venture Partners and Population Health in new China-focused deal

Aug 25, 2026·read at Endpoints ↗DealPositive

Haisco Pharmaceutical, a China-based drugmaker, has continued its active summer dealmaking by striking a new partnership.

The partnership brings together ARCH Venture Partners, a venture capital firm led by Bob Nelsen, and Population Health Partners, headed by Clive Meanwell.

The three entities aim to collaborate on biotech initiatives in China, reflecting a broader trend of foreign investors seeking opportunities in the Chinese market.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “ARCH and Population Health join China blitz with Haisco deal”

read at Endpoints ↗
95 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoJ&J’s Imaavy wins label expansion; Two approvals in JapanEndpoints
  • 2h agoFDA approves Jazz's Ziihera in frontline gastric cancerEndpoints
  • 4h agoOmicsBank raises $2.25M to bring overseas patient data to biopharmaEndpoints
  • 5h agoBristol Myers ends deal with Cellares, cell therapy manufacturer to reorgEndpoints
  • 21h agoBausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goalEndpoints